MedTrace Logo

Predicting Biomarker of Gastric Cancer Chemotherapy Response

NCT03253107 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 800

Last updated 2023-10-04

No results posted yet for this study

Summary

* discovery and validation of biomarker predicting gastric cancer chemotherapy response

* Analysis for expression level of mRNA using Next generation sequencing in gastric cancer tissue by chemotherapy response
* Analysis for expression level of miRNA using Next generation sequencing in gastric cancer tissue and blood by chemotherapy response
* Validation of mRNA and miRNA using qRT-PCR in multiple independent cohort
* Biological biomarkers-clinical factor combined prediction model of gastric cancer chemotherapy response

Conditions

Interventions

DRUG

Chemotherapy

Institutinal standard chemotherapy as first line : XP (xeloda + cisplantin) or Xelox (xeloda+oxaliplitan) +/- Herceptin

Sponsors & Collaborators

  • Kyungpook National University Hospital

    lead OTHER

Principal Investigators

  • Su Youn Nam, MD, PhD · Kyungpook National University Medical Center

Eligibility

Min Age
20 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-11-30
Primary Completion
2024-12-31
Completion
2024-12-31

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03253107 on ClinicalTrials.gov